Stiff, twitchy or wobbly—are GAD antibodies pathogenic?
Open Access
- 17 September 2008
- journal article
- editorial
- Published by Oxford University Press (OUP) in Brain
- Vol. 131 (10) , 2536-2537
Abstract
Over the last decade or so there has been increasing recognition of the importance of measuring antibodies to neuronal proteins in the diagnosis and management of disease. Such antibodies can be classified into two main groups. First, there are those that are markers for a disease process, such as the paraneoplastic antibodies against Hu, Yo, Ma2, but which are not thought to cause the disease. This is because their targets are cytoplasmic or nuclear proteins that are not exposed on the surface of the neurons, and because the patients do not respond to immunotherapies such as plasma exchange, intravenous immunoglobulins or corticosteroids. Moreover, the antibodies do not necessarily associate with specific syndromes; for instance, Hu antibodies can be found in a wide range of disorders from neuronopathy to limbic encephalitis. By contrast, the second group includes those that are not only diagnostic biomarkers but are also pathogenic (or likely to be). These bind to important membrane proteins, their epitopes exposed on the outside of the target cells; they are usually syndrome specific, e.g. the acetylcholine receptor antibodies in myasthenia gravis and, most importantly, the patients do well with treatments that reduce the levels of the antibodies.Keywords
This publication has 10 references indexed in Scilit:
- CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitisJournal of the Neurological Sciences, 2008
- Advances in the pathogenesis and treatment of patients with stiff person syndromeCurrent Neurology and Neuroscience Reports, 2008
- Autoimmunity to GABAA-receptor-associated protein in stiff-person syndromeBrain, 2006
- Serum antibodies in epilepsy and seizure-associated disordersNeurology, 2005
- Potassium channel antibody‐associated encephalopathy: a potentially immunotherapy‐responsive form of limbic encephalitisBrain, 2004
- High-Dose Intravenous Immune Globulin for Stiff-Person SyndromeNew England Journal of Medicine, 2001
- Cerebellar Ataxia With Anti–Glutamic Acid Decarboxylase AntibodiesArchives of Neurology, 2001
- Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsyNeurology, 2000
- The clinical significance of an autoimmune response against glutamic acid decarboxylaseNature Medicine, 1996
- Autoantibodies to GABA-ergic Neurons and Pancreatic Beta Cells in Stiff-Man SyndromeNew England Journal of Medicine, 1990